Zobrazeno 1 - 10
of 23
pro vyhledávání: '"van Brummelen EMJ"'
Autor:
Sonneveld P; Department of Hematology, EMN/Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Dimopoulos MA; National & Kapodistrian University of Athens, Athens, Greece., Boccadoro M; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy., Quach H; University of Melbourne & St. Vincent's Hospital, Melbourne, Australia., Ho PJ; Institute of Haematology, Royal Prince Alfred Hospital & University of Sydney, Camperdown, NSW, Australia., Beksac M; Ankara University, Ankara, Turkey., Hulin C; Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France., Antonioli E; Department of Hematology, Careggi Hospital & University of Florence, Firenze, Italy., Leleu X; University of Poitiers, CHU & Inserm 1313, Poitiers, France., Mangiacavalli S; Division of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy., Perrot A; CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France., Cavo M; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli,' Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Belotti A; Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy., Broijl A; Department of Hematology, EMN/Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Gay F; Division of Hematology 1, AOU Città della Salute e della Scienza di Torino, University of Torino & Department of Molecular Biotechnology & Health Sciences, University of Torino, Torino, Italy., Mina R; Division of Hematology 1, AOU Città della Salute e della Scienza di Torino, University of Torino & Department of Molecular Biotechnology & Health Sciences, University of Torino, Torino, Italy., van de Donk NWCJ; Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Katodritou E; Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece., Schjesvold F; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway, & KG Jebsen Center for B-cell Malignancies, University of Oslo, Oslo, Norway., Balari AS; Hematology Department, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain., Rosiñol L; Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain., Delforge M; University of Leuven, Leuven, Belgium., Roeloffzen W; University Medical Center Groningen, Groningen, The Netherlands., Silzle T; Department of Medical Oncology & Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland., Vangsted A; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Einsele H; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany., Spencer A; Malignant Haematology & Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia., Hajek R; Department of Hematooncology, University Hospital Ostrava & Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Jurczyszyn A; Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland., Lonergan S; Department of Hematology, EMN/Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Ahmadi T; Genmab US, Inc., Plainsboro, NJ, USA., Liu Y; Janssen Research & Development, LLC, Beijing, China., Wang J; Janssen Research & Development, LLC, Spring House, PA, USA., Vieyra D; Janssen Research & Development, LLC, Spring House, PA, USA., van Brummelen EMJ; Janssen Research & Development, LLC, Leiden, The Netherlands., Vanquickelberghe V; Janssen Research & Development, Beerse, Belgium., Sitthi-Amorn A; Janssen Research & Development, LLC, Spring House, PA, USA., de Boer CJ; Janssen Research & Development, LLC, Leiden, The Netherlands., Carson R; Janssen Research & Development, LLC, Spring House, PA, USA., Rodriguez-Otero P; Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona, Navarra, Spain., Bladé J; Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, & Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (GEM/PETHEMA), Barcelona, Spain., Moreau P; Hematology Department, University Hospital Hôtel-Dieu, Nantes, France.
Publikováno v:
Future oncology (London, England) [Future Oncol] 2024 Sep 17, pp. 1-21. Date of Electronic Publication: 2024 Sep 17.
Autor:
Sonneveld P; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Dimopoulos MA; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Boccadoro M; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Quach H; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Ho PJ; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Beksac M; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Hulin C; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Antonioli E; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Leleu X; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Mangiacavalli S; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Perrot A; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Cavo M; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Belotti A; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Broijl A; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Gay F; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Mina R; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Nijhof IS; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., van de Donk NWCJ; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Katodritou E; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Schjesvold F; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Sureda Balari A; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Rosiñol L; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Delforge M; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Roeloffzen W; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Silzle T; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Vangsted A; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Einsele H; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Spencer A; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Hajek R; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Jurczyszyn A; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Lonergan S; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Ahmadi T; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Liu Y; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Wang J; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Vieyra D; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., van Brummelen EMJ; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Vanquickelberghe V; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Sitthi-Amorn A; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., de Boer CJ; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Carson R; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Rodriguez-Otero P; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Bladé J; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.)., Moreau P; From Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) - all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) - both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi Hospital and University of Florence, Florence (E.A.), the Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia (S.M.), IRCCS AOU di Bologna, Istituto di Ematologia 'Seràgnoli,' and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (M.C.), and the Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia (A. Belotti) - all in Italy; the University of Melbourne and St. Vincent's Hospital, Melbourne, VIC (H.Q.), the Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and the Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC (A.S.) - all in Australia; Ankara University, Ankara, Turkey (M. Beksac); the Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac (C.H.), the University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers (X.L.), CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, Université Paul Sabatier, Service d'Hématologie, Toulouse (A.P.), and the Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.) - all in France; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, and KG Jebsen Center for B-cell Malignancies, University of Oslo - both in Oslo (F.S.); the Hematology Department, Institut Català d'Oncologia-Hospitalet, Instituto de Investigación Biomédica de Bellvitge (A.S.B.), University of Barcelona (A.S.B.), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (L.R., J.B.), and Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (J.B.), Barcelona, and the Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona (P.R.-O.) - all in Spain; the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Beerse (V.V.) - both in Belgium; the Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (T.S.); the Department of Hematology, Rigshospitalet, Copenhagen (A.V.); the Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany (H.E.); the Department of Hemato-oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava - both in Ostrava, Czech Republic (R.H.); the Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland (A.J.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Beijing (Y.L.); and Janssen Research and Development, Spring House, PA (J.W., D.V., A.S.-A., R.C.).
Publikováno v:
The New England journal of medicine [N Engl J Med] 2024 Jan 25; Vol. 390 (4), pp. 301-313. Date of Electronic Publication: 2023 Dec 12.
Autor:
Radanovic I; Centre for Human Drug Research, Leiden, Netherlands.; Leiden University Medical Center, Leiden, Netherlands., Klarenbeek N; Centre for Human Drug Research, Leiden, Netherlands., Rissmann R; Centre for Human Drug Research, Leiden, Netherlands.; Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands., Groeneveld GJ; Centre for Human Drug Research, Leiden, Netherlands.; Leiden University Medical Center, Leiden, Netherlands., van Brummelen EMJ; Centre for Human Drug Research, Leiden, Netherlands., Moerland M; Centre for Human Drug Research, Leiden, Netherlands.; Leiden University Medical Center, Leiden, Netherlands., Bosch JJ; Centre for Human Drug Research, Leiden, Netherlands.; Leiden University Medical Center, Leiden, Netherlands.
Publikováno v:
Frontiers in oncology [Front Oncol] 2022 Aug 29; Vol. 12, pp. 954806. Date of Electronic Publication: 2022 Aug 29 (Print Publication: 2022).
Autor:
Thijssen E; Centre for Human Drug Research (CHDR), Zernikedreef 8, 2333 CL, Leiden, Netherlands; Leiden University Medical Centre (LUMC), Albinusdreef 2, 2333 ZA, Leiden, Netherlands., den Heijer JM; Centre for Human Drug Research (CHDR), Zernikedreef 8, 2333 CL, Leiden, Netherlands; Leiden University Medical Centre (LUMC), Albinusdreef 2, 2333 ZA, Leiden, Netherlands., Puibert D; Ferrer HealthTech, Diagonal 549, 08029, Barcelona, Spain., van Brummelen EMJ; Centre for Human Drug Research (CHDR), Zernikedreef 8, 2333 CL, Leiden, Netherlands., Naranda T; Alexza Pharmaceuticals, 2091 Stierlin Court, Mountain View, CA, 94043, USA., Groeneveld GJ; Centre for Human Drug Research (CHDR), Zernikedreef 8, 2333 CL, Leiden, Netherlands; Leiden University Medical Centre (LUMC), Albinusdreef 2, 2333 ZA, Leiden, Netherlands. Electronic address: ggroeneveld@chdr.nl.
Publikováno v:
Parkinsonism & related disorders [Parkinsonism Relat Disord] 2022 Apr; Vol. 97, pp. 84-90. Date of Electronic Publication: 2022 Mar 08.
Autor:
Hijma HJ; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Centre, Leiden, The Netherlands., van Brummelen EMJ; Centre for Human Drug Research, Leiden, The Netherlands., Siebenga PS; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Centre, Leiden, The Netherlands., Groeneveld GJ; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Centre, Leiden, The Netherlands.
Publikováno v:
Clinical and translational science [Clin Transl Sci] 2022 Apr; Vol. 15 (4), pp. 981-993. Date of Electronic Publication: 2021 Dec 27.
Autor:
de Las Heras B; Labcorp Drug Development Inc., headquarters in Burlington, North Carolina, USA.; Madrid Medical Doctors Association, Madrid, Spain., Bouyoucef-Cherchalli D; Labcorp Drug Development Inc., headquarters in Burlington, North Carolina, USA., Reeve L; Labcorp Drug Development Inc., headquarters in Burlington, North Carolina, USA., Reichl A; Labcorp Drug Development Inc., headquarters in Burlington, North Carolina, USA., Mandarino D; Labcorp Drug Development Inc., headquarters in Burlington, North Carolina, USA., Flach S; Labcorp Drug Development Inc., headquarters in Burlington, North Carolina, USA., Vidal L; Labcorp Drug Development Inc., headquarters in Burlington, North Carolina, USA., van Brummelen EMJ; Centre for Human Drug Research, Leiden, The Netherlands., Steeghs N; Netherlands Cancer Institute, Amsterdam, The Netherlands.
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Feb; Vol. 88 (4), pp. 1773-1784. Date of Electronic Publication: 2021 Oct 19.
Autor:
Moss LM; Centre for Human Drug Research, Leiden, the Netherlands.; Leiden University, Leiden, the Netherlands., Berends CL; Centre for Human Drug Research, Leiden, the Netherlands.; Leiden University, Leiden, the Netherlands., van Brummelen EMJ; Centre for Human Drug Research, Leiden, the Netherlands., Kamerling IMC; Centre for Human Drug Research, Leiden, the Netherlands.; Leiden University, Leiden, the Netherlands., Klaassen ES; Centre for Human Drug Research, Leiden, the Netherlands., Bergmann K; Centre for Human Drug Research, Leiden, the Netherlands., Ville V; Stragen France, Lyon, France., Juarez-Perez V; Stragen France, Lyon, France., Benichou AC; Stragen Services, Lyon, France., Groeneveld GJ; Centre for Human Drug Research, Leiden, the Netherlands.; Leiden University, Leiden, the Netherlands.
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Jan; Vol. 88 (1), pp. 103-114. Date of Electronic Publication: 2021 Jul 16.
Autor:
Makai-Bölöni S; Centre for Human Drug Research, Leiden, the Netherlands.; Leiden University Medical Centre, Leiden, the Netherlands., Thijssen E; Centre for Human Drug Research, Leiden, the Netherlands.; Leiden University Medical Centre, Leiden, the Netherlands., van Brummelen EMJ; Centre for Human Drug Research, Leiden, the Netherlands., Groeneveld GJ; Centre for Human Drug Research, Leiden, the Netherlands.; Leiden University Medical Centre, Leiden, the Netherlands., Doll RJ; Centre for Human Drug Research, Leiden, the Netherlands.
Publikováno v:
PloS one [PLoS One] 2021 Dec 07; Vol. 16 (12), pp. e0260783. Date of Electronic Publication: 2021 Dec 07 (Print Publication: 2021).
Autor:
Mellion ML; Fulcrum Therapeutics, Cambridge, MA, USA., Ronco L; Fulcrum Therapeutics, Cambridge, MA, USA., Berends CL; Centre for Human Drug Research (CHDR), Leiden, The Netherlands., Pagan L; Centre for Human Drug Research (CHDR), Leiden, The Netherlands., Brooks S; Centre for Human Drug Research (CHDR), Leiden, The Netherlands., van Esdonk MJ; Centre for Human Drug Research (CHDR), Leiden, The Netherlands., van Brummelen EMJ; Centre for Human Drug Research (CHDR), Leiden, The Netherlands., Odueyungbo A; Fulcrum Therapeutics, Cambridge, MA, USA., Thompson LA; Fulcrum Therapeutics, Cambridge, MA, USA., Hage M; Fulcrum Therapeutics, Cambridge, MA, USA., Badrising UA; Leiden University Medical Centre, Leiden, The Netherlands., Raines S; 2b Analytics, Wallingford, PA, USA., Tracewell WG; Nuventra Pharma Sciences, Durham, NC, USA., van Engelen B; Radboud University Medical Centre, Nijmegen, The Netherlands., Cadavid D; Fulcrum Therapeutics, Cambridge, MA, USA., Groeneveld GJ; Centre for Human Drug Research (CHDR), Leiden, The Netherlands.; Leiden University Medical Centre, Leiden, The Netherlands.
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2021 Dec; Vol. 87 (12), pp. 4658-4669. Date of Electronic Publication: 2021 May 14.
Autor:
van Brummelen EMJ; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Huijberts S; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Herpen C; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Desar I; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Opdam F; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Geel R; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, The Netherlands., Marchetti S; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Steeghs N; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Monkhorst K; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Thijssen B; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Rosing H; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Huitema A; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Beijnen J; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Utrecht University, Utrecht, The Netherlands., Bernards R; Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Utrecht University, Utrecht, The Netherlands., Schellens J; Utrecht University, Utrecht, The Netherlands.
Publikováno v:
The oncologist [Oncologist] 2021 Apr; Vol. 26 (4), pp. 290-e545. Date of Electronic Publication: 2020 Dec 29.